Dice CEO: Energy, T...
Health Care: Health Services
Enzo Biochem Inc. (ENZ: NYSE)
$1.79 -0.03 | -1.65%
06/01/12 - 04:03 PM ET
Company Income Statement
| Jul 2011 | Jul 2010 | Jul 2009 | Jul 2008 | |
| Sales | 102.03M | 97.08M | 89.57M | 77.80M |
| Cost of Sales | 49.35M | 47.85M | 49.60M | 38.08M |
| Gross Operating Profit | 52.68M | 49.23M | 39.97M | 39.72M |
| Selling, General, and Administrative Expenses | 53.33M | 55.57M | 50.70M | 43.72M |
| Research & Development | 7.81M | 9.70M | 9.22M | 8.64M |
| Operating Income before D & A (EBITDA) | -8.46M | -16.04M | -19.94M | -12.64M |
| Depreciation & Amortization | 4.47M | 4.27M | 3.46M | 2.15M |
| Interest Income | 11.00K | 19.00K | 581.00K | 3.70M |
| Other Income - Net | 94.00K | -222.00K | -825.00K | 198.00K |
| Special Income / Charges | 0.00 | -1.75M | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -12.82M | -22.26M | -23.65M | -10.89M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -12.82M | -22.26M | -23.65M | -10.89M |
| Income Taxes | 137.00K | -28.00K | -87.00K | -239.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -12.96M | -22.23M | -23.56M | -10.65M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -12.96M | -22.23M | -23.56M | -10.65M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -12.96M | -22.23M | -23.56M | -10.65M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-12.96M | -20.49M | -23.56M | -10.65M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -12.96M | -22.23M | -23.56M | -10.65M |
| Basic EPS from Continuing Ops. | -0.34 | -0.59 | -0.63 | -0.29 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.34 | -0.59 | -0.63 | -0.29 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.34 | -0.59 | -0.63 | -0.29 |
| Basic Normalized Net Income/Share | -0.34 | -0.54 | -0.63 | -0.29 |
| EPS fr Continuing Ops. | -0.34 | -0.59 | -0.63 | -0.29 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.34 | -0.59 | -0.63 | -0.29 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.34 | -0.59 | -0.63 | -0.29 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.34 | -0.54 | -0.63 | -0.29 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ENZ
- Portfolio NameUser Type
- UserBarron's Insider Purchases ...
- ContributorStockerblog.com Gene Therap...
- Userkelvinenz Portfolio 1
- UserS-0022
- UserTraderSteveUK Portfolio 1
- UserRT_in_CA
- UserSo far, I'm beating the S&a...
- Userjwcarmack Portfolio 1
- Userrecentoutperform070824
- Usersfields Portfolio 1
Latest ENZ Headlines from TheStreet
- Thursday Earnings Live Blog 10.14.10 | 04:10 pm
- Investors May See Upside Down Under 09.16.10 | 08:09 am
- Enzo Biochem 1Q Loss Narrows On Revenue Boost 12.10.09 | 04:12 pm
- Enzo Biochem 4Q Loss Widens On Costs 10.14.09 | 06:10 pm
- Tuesday's Health Winners & Losers 10.16.07 | 04:10 pm
- Enzo Biochem Falls on Court Dismissal 09.07.07 | 02:09 pm
- Friday's Health Winners & Losers 09.07.07 | 02:09 pm
- Checking Up on Biotech 08.10.07 | 04:08 pm
- Monday's Health Winners & Losers 10.16.06 | 02:10 pm
- Enzo Biochem Loss Widens 10.16.06 | 11:10 am
Press Releases for ENZ
- Enzo Biochem Launch Of Test For Measuring Risk Of Colorectal Cancer Underscores Growing Role Of Molecular Diagnostics - Business Wire 04.10.12 | 08:04 am
- Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform Details At ESCMID London Meeting - Business Wire 04.01.12 | 04:04 pm
- Enzo Biochem To Present At Needham Healthcare Conference - Business Wire 03.27.12 | 12:03 pm
- Enzo Biochem Announces Expanded Distribution Agreement With Japan’s Cosmo Bio - Business Wire 03.20.12 | 07:03 am
- Enzo Biochem’s Clinical Laboratory Applies For NY State Health Department Approval For First Assay Based On Its AmpiProbe™ Amplification Platform - Business Wire 03.13.12 | 07:03 am
- Enzo Biochem Reports Improved Second Quarter Results - Business Wire 03.12.12 | 04:03 pm
- Enzo Biochem To Present New AmpiProbe™ Nucleic Acid Amplification Platform At ESCMID London Meeting - Business Wire 03.08.12 | 08:03 am
- Enzo Biochem Schedules Teleconference To Discuss 2012 Second Quarter Results On March 13, 2012 At 8:30 AM E.T. - Business Wire 03.08.12 | 07:03 am
- Enzo Biochem Receives Approval For Novel Blood Based Test For Colorectal Cancer Risk - Business Wire 02.21.12 | 08:02 am
- Enzo Biochem To Present At 2012 Leerink Swann Global Healthcare Conference - Business Wire 02.10.12 | 12:02 pm
Partner Headlines for ENZ
- Investors Should Wait Out Quest & LabCorp - Seeking Alpha 02.16.12 | 09:02 am
- Enzo Biochem: Personalized Medicine Is More Than Targeted Therapeutics - Seeking Alpha 04.03.11 | 07:04 am
- Competitive Technologies: Short Squeeze Coming or Another Leg Down? - Seeking Alpha 08.25.10 | 09:08 am
- Top 5 Percentage Gainers On NYSE (DV, CKH, ENZ, LAD, CMG) - Benzinga 07.23.10 | 03:07 pm
- MB FINANCL INC (MBFI) - Profit Tracks - Zacks 04.13.10 | 01:04 am
- UPDATE 2-Enzo wins round in Applera patent fight - Reuters 03.26.10 | 04:03 pm
